The Smart, Savvy Science Driving Viral Vector Scale-Up

Following decades of research and clinical development, despite obstacles along the way, gene therapy breakthroughs are now happening fast and furiously. Researchers worldwide are forging ahead with promising new drug candidates, bringing medicine closer than ever to treating rare and widespread diseases through the power of DNA.

The expanding clinical possibilities indicate that conventional small-scale, laboratory-based production methods will soon be insufficient. Manufacturers must adopt scalable, reliable, and efficient approaches for cell culture and viral vector production to meet the escalating demand for gene therapy.

After the acquisition of CEVEC Pharmaceuticals, a leading German company specializing in high-performance cell lines and viral vector manufacturing technologies, Cytiva is committed to providing innovative solutions to support the growing field of cell and gene therapy. Here, Clive Glover, Ph.D., Viral Vector Business Leader, Cytiva, discusses cutting-edge strategies, including alternatives to plasmid-based transient transfection, aimed at addressing current process challenges and bringing revolutionary treatments to patients in need.